Investigational Agent Shows Benefit in Myasthenia Gravis
The investigational monoclonal antibody batoclimab led to significant improvement in activities of daily living in people with generalized myasthenia gravis (gMG), a multicenter phase III trial found. The rate of sustained improvement on Myasthenia Gravis Activities of Daily Living (MG-ADL) scores for antibody-positive patients in the first treatment cycle was 58.2% in the batoclimab group […]